Treatment of Systemic Mastocytosis With Tamoxifen
Observational Model: Case-Only, Time Perspective: Prospective
Stability or reduction of the percent bone marrow involvement by mastocytosis, including stable mast cell morphology and phenotype.
up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 20 mg/day and the duration of treatment will be for one year.
Joseph H Butterfield, MD
United States: Institutional Review Board
|Mayo Clinic||Rochester, Minnesota 55905|